Comparative oral toxicity of coenzyme Q10 and its (2Z)-isomer in rats: Single and four-week repeated dose toxicity studies

Journal of Nutritional Science and Vitaminology

Volumn 52, Issue 1, 2006, Pages 9-20

  Hatakeyama, Shigeki ^a   Kawase, Shigeo ^a   Yoshimura, Ikuo ^b  

^a KYORIN PHARMACEUTICAL CO LTD   (Japan)

^b NISSHIN SEIFUN GROUP INC   (Japan)

Author keywords

Coenzyme Q10; CoQ10; Ubidecarenone; Ubiquinone

Indexed keywords

UBIDECARENONE;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; FEMALE; ISOMER; MALE; NONHUMAN; RAT; TERATOGENICITY; TOXICOLOGICAL PARAMETERS;

ANIMALS; BODY WEIGHT; DOSE-RESPONSE RELATIONSHIP, DRUG; EATING; FEMALE; HYDROGEN-ION CONCENTRATION; ISOMERISM; LUNG; MALE; ORGAN SIZE; PLATELET COUNT; PLEURA; PROTEINURIA; RATS; RATS, WISTAR; UBIQUINONE; URINE;

ANIMALIA;

EID: 33645762968     PISSN: 03014800     EISSN: 18817742     Source Type: Journal    
DOI: 10.3177/jnsv.52.9     Document Type: Article

References (20)

1. 10: A new drug for cardiovascular disease. J Clin Pharmacol 30: 596-608.
2. Rüegg R, Gloor U, Goel RN, Ryser G, Wiss O, Isler O. 1959. Synthese von Ubichinon (45) und Ubichinon (50). Helv Chim Acta 42: 2612-2621.
3. 9, 2,3-dimethyl-5-solanesylbenzoquinone (Q·254), and a vitamin K analog. J Am Chem Soc 81: 5000.
4. 10 by partial synthesis. In: Biomedical and Clinical Aspects of Coenzyme Q (Folkers K, Yamamura Y, eds), vol 3, p 19-30. Elsevier/North-Holland, Amsterdam.
5. 10 and integrated clinical research on therapy of disease. In: Coenzyme Q (Lenaz G, ed), p 457-478. John Wiley and Sons, Ltd, New York.
6. 10). In: PDR for Nutritional Supplements, p 103-107. Thompson PDR, Montvale, NJ, USA.
7. 10 (First report): Acute toxicity study in mice and rats, and subacute and chronic toxicities in rats. Pharmacometrics 6: 769-779.
8. Pharmaceutical and Cosmetic Division, Pharmaceutical Affairs Bureau, Japanese Ministry of Health and Welfare. 1994. Japanese Guidelines for Nonclinical Studies of Drugs Manual. Yakuji Nippo, Ltd, Tokyo.
9. Anonymous. 2004. Ubidecarenone. In: European Pharmacopoeia, 5th ed. p 2657-2658. European Directorate for the Quality of Medicines, Strasbourg, France.
10. Anonymous. 2005. Ubidecarenone. In: The United States Pharmacopoeia The National Formulary USP 28 NF 23, p 2132. United States Pharmacopeial Convention, Rockville, USA.
11. Anonymous. 2005. Phytonadione. In: The United States Pharmacopoeia The National Formulary USP 28 NF 23. p 1557-1558. United States Pharmacopeial Convention. Rockville, USA.
12. Merenstein K, Hathaway WE, Miller RW, Paulson JA, Rowley DL. 1993. Controversies concerning vitamin K and the newborn. Pediatrics 91: 1001-1002.
13. Von Kries R, Hanawa Y. 1993. Neonatal vitamin K prophylaxis. Report of scientific and standardization subcommittee on perinatal haemostasis. Thromb Haemost 69: 293-295.
14. Zipursky A. 1999. Prevention of vitamin K deficiency bleeding in newborns. Br J Haematol 104: 430-437.
15. Åberg F, Appelkvist EL, Dallner G, Ernster L. 1992. Distribution and redox state of ubiquinones in rat and human tissues. Arch Biochem Biophys 295: 230-234.
16. Fujita T, Matsuura T, Takamatsu T, Tsutsumi J, Kinoshita K, Katayama K, Miyao K, Hamamura K, Kijima S, Shirato M, Baba S. 1972. Studies on metabolism of ubiquinone-10. I. Mainly absorption, tissue distribution and excretion in rats and rabbits. Oyo Yakuri 6: 695-706 (in Japanese).
17. Fujita T, Matsuura T, Takamatsu T, Hamamura K, Kijima S, Kinoshita K, Tsutsumi J, Katayama K, Miyao K, Baba S, Shirato M. 1972. Studies on metabolism of ubiquinone-10). II. Metabolism in blood, liver and urine of rats and rabbits. Oyo Yakuri 6: 707-715 (in Japanese).
18. 7. Pharmacometrics 4: 659-672.
19. 9 (First report): Acute, subacute and chronic toxicities. Pharmacometrics 3: 147-154.
20. Tajima Y. 1986. Biological Property Data on Laboratory Animals. Soft Science Co. Ltd. Tokyo.